Group 1 - The core viewpoint of the article highlights that Peijia Medical-B (09996) has seen a stock price increase of over 3%, currently trading at HKD 5.92 with a transaction volume of HKD 8.93 million [1] - On December 5, Peijia Medical announced that its Executive Director, CEO, and Chairman, Dr. Zhang Yi, will begin purchasing company shares in the open market starting December 1, 2025, with a total investment not exceeding HKD 15 million [1] - Dr. Zhang does not rule out the possibility of further increasing his shareholding in the company at an appropriate time, in accordance with applicable laws and regulations [1] Group 2 - CITIC Securities released a report indicating that the company's TAVR products are experiencing continuous growth in volume and steadily increasing market share [1] - The GeminiOneTEER system, TaurusTrio aortic regurgitation valve, and TaurusNXT dry valve TAVR are expected to receive intensive approvals between the end of 2025 and 2026, driving accelerated growth in the valve business [1] - The MonarQ tricuspid valve system has initiated global clinical trials, and the cutting-edge technology business has secured external financing, indicating a clear path for innovation and international expansion [1]
港股异动 沛嘉医疗-B(09996)现涨超3% 董事长于公开市场增持股份 多款产品即将取得重要进展